Meteneprost | CAS#61263-35-2 | abortifacent

MedKoo Cat#: 585315 | Name: Meteneprost

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Meteneprost is a compound tested for use as early pregnancy terminater, and is derivative of both PGE2 & PGF2alpha.

Chemical Structure

Meteneprost

CAS#61263-35-2

Theoretical Analysis

MedKoo Cat#: 585315

Name: Meteneprost

CAS#: 61263-35-2

Chemical Formula: C23H38O4

Exact Mass: 378.2770

Molecular Weight: 378.55

Elemental Analysis: C, 72.98; H, 10.12; O, 16.91

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Meteneprost; U 46785; U 46,785; U46785; U46,785; U-46785; U-46,785;

IUPAC/Chemical Name

(Z)-7-[(1R,2R,3R)-3-hydroxy-2-[(E,3R)-3-hydroxy-4,4-dimethyloct-1-enyl]-5-methylidenecyclopentyl]hept-5-enoic acid

InChi Key

WMLGLMGSFIXSGO-KTXJXPLISA-N

InChi Code

InChI=1S/C23H38O4/c1-5-6-15-23(3,4)21(25)14-13-19-18(17(2)16-20(19)24)11-9-7-8-10-12-22(26)27/h7,9,13-14,18-21,24-25H,2,5-6,8,10-12,15-16H2,1,3-4H3,(H,26,27)/b9-7-,14-13+/t18-,19+,20+,21+/m0/s1

SMILES Code

O=C(O)CCC/C=C\C[C@@H]1[C@@H](/C=C/[C@@H](O)C(C)(C)CCCC)[C@H](O)CC1=C

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 378.55 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: A multicentre randomized comparative clinical trial of 200 mg RU486 (mifepristone) single dose followed by either 5 mg 9-methylene PGE(2) gel (meteneprost) or 600 microg oral PGE(1) (misoprostol) for termination of early pregnancy within 28 days of missed menstrual period. ICMR Task Force Study. Indian Council of Medical Research. Contraception. 2000 Sep;62(3):125-30. PubMed PMID: 11124359. 2: Kimball FA, Cornette JC, Bundy GL, Kirton KT. Plasma concentrations of 9-deoxo-16-dimethyl-9-methylene-PGE2 in rhesus monkeys after administration by various routes. Prostaglandins. 1980 Sep;20(3):559-69. PubMed PMID: 7422900. 3: Shapiro AG, Lasseter K, Cobiella A, Domenzain M. Intravaginal administration of 9-deoxo-9-methylene-16,16-dimethyl PGE2 for cervical dilation prior to suction curettage. Int J Gynaecol Obstet. 1982 Apr;20(2):137-40. PubMed PMID: 6125434. 4: Brenner PF, Marrs RP, Roy S, Mishell DR Jr. Termination of early gestation with 9-deoxo-16,16-dimethyl-9-methylene prostaglandin E2. Contraception. 1982 Sep;26(3):261-77. PubMed PMID: 6184197. 5: Nyholm HC, Mikkelsen AL, Secher NJ. Pretreatment of the cervix with 9-deoxy-16,16-dimethyl-9-methylene-prostaglandin E2 (Meteneprost) vaginal pessaries before first trimester legal abortion in nulliparae. J Obstet Gynaecol (Lahore). 1988;8(3):210-3. PubMed PMID: 12342310. 6: Gréen K, Kimball FA, Thornburgh BA, WickremaSinha AJ. Quantitative determination of 9-deoxo-16, 16-dimethyl-9-methylene-PGE2 in human plasma by GC-MS, RIA and HPLC. Prostaglandins. 1980 Oct;20(4):767-80. PubMed PMID: 7465866. 7: Steffenrud S. Metabolism of 9-deoxo-16,16-dimethyl-9-methylene prostaglandin E2 in humans. Drug Metab Dispos. 1983 May-Jun;11(3):255-65. PubMed PMID: 6135585. 8: Ballard CA. The vaginal administration of 9-deoxo-16,16-dimethyl-9-methylene PGE2 for second trimester abortion. Contraception. 1981 Aug;24(2):151-7. PubMed PMID: 7297067. 9: Bygdeman M, Christensen N, Gréen K, Lundström V. Mid-trimester abortion by vaginal administration of 9-deoxo-16, 16-dimethyl-9-methylene-PGE2. Contraception. 1980 Aug;22(2):153-64. PubMed PMID: 7449380. 10: Moberg PJ, Bygdeman M, Carnsjö LG, Frankman O, Gréen K. Pre-abortion treatment with a single vaginal suppository containing 9-deoxo-16,16-dimethyl-9-methylene PGE2 in late first and early second trimester pregnancies. Acta Obstet Gynecol Scand Suppl. 1983;113:137-40. PubMed PMID: 6574668. 11: Bremme K, Eneroth P, Bygdeman M. Maternal serum hormone changes during abortion induced with 9-deoxo-16, 16-dimethyl-9-methylene prostaglandin E2. J Endocrinol Invest. 1982 Nov-Dec;5(6):387-91. PubMed PMID: 7169514. 12: Christensen NJ, Bygdeman M, Greén K, Jonasson H, Rundgren M, Wallin CJ, Vesterqvist O, Leksell LG. The prostaglandin-analogue-9-deoxo-16,16-dimethyl-9-methylene-PGE2 inhibits the antidiuretic effect of vasopressin (AVP) in the conscious sheep. Pflugers Arch. 1984 Dec;402(4):360-3. PubMed PMID: 6522243. 13: Leksell LG, Christensen NJ, Vesterqvist O, Wallin CJ. Water diuretic effect of intravenously administered 9-deoxo-16, 16-dimethyl-9-methylene-PGE2 in conscious man. Clin Physiol. 1984 Dec;4(6):449-59. PubMed PMID: 6542832. 14: Norström A, Bryman I, Lindblom B, Christensen NJ. Effects of 9-deoxo-16,16-dimethyl-9-methylene PGE2 on muscle contractile activity and collagen synthesis in the human cervix. Prostaglandins. 1985 Mar;29(3):337-46. PubMed PMID: 4001435. 15: Gréen K, Vesterqvist O, Bygdeman M, Christenssen NJ, Bergström S. Plasma levels of 9-deoxo-16,16-dimethyl-9-methylene-PGE2 in connection with its development as an abortifacient. Prostaglandins. 1982 Oct;24(4):451-66. PubMed PMID: 7178484. 16: Gréen K, Bygdeman M, Swahn ML, Vesterqvist O, Christensen NJ. Development of a vaginal gel containing 9-deoxo-16,16-dimethyl-9-methylene PGE2 for cervical dilatation and pregnancy termination. Prostaglandins Leukot Essent Fatty Acids. 1988 Aug;33(2):121-7. PubMed PMID: 3174718. 17: Bundy GL, Kimball FA, Robert A, Aiken JW, Maxey KM, Sebek OK, Nelson NA, Sih JC, Miller WL, Hsi RS. Synthesis and biological activity of 9-deoxo-9-methylene and related prostaglandins. Adv Prostaglandin Thromboxane Res. 1980;6:355-63. PubMed PMID: 7386275. 18: Somell C, Olund A. Cervical dilatation with meteneprost vaginal suppositories in first trimester abortion. Contraception. 1986 Feb;33(2):189-94. PubMed PMID: 3698595. 19: Friedli A, De Grandi P. [Preoperative dilatation of the cervix uteri by vaginal application of 9-deoxo-16, 16-dimethyl-9-methylene PGE2 in pregnancy interruption during the 1st trimester. Double-blind clinical study]. J Gynecol Obstet Biol Reprod (Paris). 1986;15(2):215-21. French. PubMed PMID: 3522723. 20: Maria B, André-David F, Oury JF, Stampf F, Bresson E, Rosenberg P. [Cervical dilatation by use of a vaginal suppository of meteneprost before voluntary interruption of the pregnancy in the first trimester]. J Gynecol Obstet Biol Reprod (Paris). 1987;16(5):637-42. French. PubMed PMID: 3668189.